INmune Bio Inc. will host a webinar on February 27, 2026, discussing XPro1595 for early Alzheimer’s disease treatment, following Phase 2 MINDFuL trial completion and FDA feedback, supporting advancement to a registrational study in Alzheimer’s patients with inflammation biomarkers. The webinar will include presentations on trial results, FDA feedback, and a strategic roadmap to Phase 3, featuring clinical experts Dr. Michael Woodward and Dr. Sharon Cohen. XPro1595 is a next-gen TNF inhibitor targeting sTNF to restore immune homeostasis in the brain. For registration and more information, visit the provided links.

Read more at GlobeNewswire: INmune Bio to Detail XPro1595 Registrational Strategy in